Clinical study to investigate recurrence efficacy on a combined use of radiofrequency ablation therapy and auto-gamma/delta T cell therapy for hepatitis C virus-related hepatocellular carcinoma patients.

Clinical study to investigate recurrence efficacy on a combined use of radiofrequency ablation therapy and auto-gamma/delta T cell therapy for hepatitis C virus-related hepatocellular carcinoma patients. - Clinical study to investigate recurrence efficacy on a combined use of radiofrequency ablation therapy and auto-gamma/delta T cell therapy for hepatitis C virus-related hepatocellular carcinoma patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004583

Enrollment

Registered

2010-11-18

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C virus-related hepatocellular carcinoma

Interventions

Auto-gamma/delta T cell therapy repeats 6 times every 2 weeks. Two days after first auto-gamma/delta T cell therapy, patients receive radiofrequency ablation therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hepatitis C virus-related hepatocellular carcinoma patients who meet the following: - 3 or fewer lesions, and each maximum diameter 3cm or less; - Child-Pugh score 5-7; - Performance status 0-1; - No serious abnormality in heart, lung, bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: - Active enteritis; - Active autoimmune diseases; - Active infections; - Other cancers; - Other serious complications; - Continuous systemic administration of steroids.

Design outcomes

Primary

Measure	Time frame
Recurrence-free survival rate	—

Secondary

Measure	Time frame
Recurrence-free survival Overall survival Disease-specific survival Immunological responses Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026